KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gilead Sciences (GILD) Research & Development (2016 - 2025)

Historic Research & Development for Gilead Sciences (GILD) over the last 17 years, with Q3 2025 value amounting to $1.3 billion.

  • Gilead Sciences' Research & Development fell 351.25% to $1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $5.9 billion, marking a year-over-year increase of 322.52%. This contributed to the annual value of $5.9 billion for FY2024, which is 330.54% up from last year.
  • According to the latest figures from Q3 2025, Gilead Sciences' Research & Development is $1.3 billion, which was down 351.25% from $1.5 billion recorded in Q2 2025.
  • Over the past 5 years, Gilead Sciences' Research & Development peaked at $1.6 billion during Q4 2024, and registered a low of $1.1 billion during Q1 2021.
  • For the 5-year period, Gilead Sciences' Research & Development averaged around $1.3 billion, with its median value being $1.4 billion (2025).
  • In the last 5 years, Gilead Sciences' Research & Development crashed by 1593.53% in 2021 and then surged by 2767.7% in 2023.
  • Over the past 5 years, Gilead Sciences' Research & Development (Quarter) stood at $1.4 billion in 2021, then increased by 13.99% to $1.5 billion in 2022, then decreased by 9.04% to $1.4 billion in 2023, then rose by 16.55% to $1.6 billion in 2024, then decreased by 17.98% to $1.3 billion in 2025.
  • Its Research & Development stands at $1.3 billion for Q3 2025, versus $1.5 billion for Q2 2025 and $1.4 billion for Q1 2025.